Literature DB >> 28466385

Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS).

Erden Atilla1, Pinar Ataca Atilla2, Sinem Civriz Bozdag2, Meltem Kurt Yuksel2, Selami Kocak Toprak2, Pervin Topcuoglu2, Bengu Nisa Akay3, Hatice Sanli2,3, Gunhan Gurman2, Muhit Ozcan2.   

Abstract

Cutaneous T cell lymphoma is a heterogeneous group of lymphoproliferative disorders with different clinical behavior and prognosis in which malignant T cells accumulate in the skin. In the relapsed/refractory stage, treatment strategy varies depending on clinical perspective. We retrospectively evaluated advanced stage relapse or refractory mycosis fungoides and Sezary syndrome patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at our hospital. The overall response rate was 25%, while the disease progressed and relapsed after transplant in 38% of patients. Allo-HSCT may be a reasonable treatment option in the relapsed/refractory stage.

Entities:  

Keywords:  Allogeneic hematopoietic stem cell transplantation; Mycosis fungoides; Sezary syndrome

Mesh：

Year:  2017        PMID： 28466385     DOI： 10.1007/s12185-017-2245-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  13 in total

1.  A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome.

Authors:  Peggy A Wu; Youn H Kim; Phillip W Lavori; Richard T Hoppe; Keith E Stockerl-Goldstein
Journal:  Biol Blood Marrow Transplant       Date:  2009-08       Impact factor: 5.742

2.  Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis.

Authors:  Rafael F Duarte; Ariane Boumendil; Francesco Onida; Ian Gabriel; Reyes Arranz; William Arcese; Xavier Poiré; Guido Kobbe; Franco Narni; Agostino Cortelezzi; Eduardo Olavarría; Norbert Schmitz; Anna Sureda; Peter Dreger
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

3.  Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.

Authors:  Elise A Olsen; Sean Whittaker; Youn H Kim; Madeleine Duvic; H Miles Prince; Stuart R Lessin; Gary S Wood; Rein Willemze; Marie-France Demierre; Nicola Pimpinelli; Maria Grazia Bernengo; Pablo L Ortiz-Romero; Martine Bagot; Teresa Estrach; Joan Guitart; Robert Knobler; José Antonio Sanches; Keiji Iwatsuki; Makoto Sugaya; Reinhard Dummer; Mark Pittelkow; Richard Hoppe; Sareeta Parker; Larisa Geskin; Lauren Pinter-Brown; Michael Girardi; Günter Burg; Annamari Ranki; Maartan Vermeer; Steven Horwitz; Peter Heald; Steve Rosen; Lorenzo Cerroni; Brigette Dreno; Eric C Vonderheid
Journal:  J Clin Oncol       Date:  2011-05-16       Impact factor: 44.544

4.  Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome.

Authors:  Maxim Polansky; Rakhshandra Talpur; Seema Daulat; Chitra Hosing; Bouthaina Dabaja; Madeleine Duvic
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-10-05

5.  TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).

Authors:  Youn H Kim; Rein Willemze; Nicola Pimpinelli; Sean Whittaker; Elise A Olsen; Annamari Ranki; Reinhard Dummer; Richard T Hoppe
Journal:  Blood       Date:  2007-03-05       Impact factor: 22.113

6.  Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Rafael F Duarte; Carmen Canals; Francesco Onida; Ian H Gabriel; Reyes Arranz; William Arcese; Augustin Ferrant; Guido Kobbe; Franco Narni; Giorgio Lambertenghi Deliliers; Eduardo Olavarría; Norbert Schmitz; Anna Sureda
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

Review 7.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

8.  Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas.

Authors:  Adèle de Masson; Marie Beylot-Barry; Jean-David Bouaziz; Régis Peffault de Latour; François Aubin; Sylvain Garciaz; Michel d'Incan; Olivier Dereure; Stéphane Dalle; Anne Dompmartin; Felipe Suarez; Maxime Battistella; Marie-Dominique Vignon-Pennamen; Jacqueline Rivet; Henri Adamski; Pauline Brice; Sylvie François; Séverine Lissandre; Pascal Turlure; Ewa Wierzbicka-Hainaut; Eolia Brissot; Rémy Dulery; Sophie Servais; Aurélie Ravinet; Reza Tabrizi; Saskia Ingen-Housz-Oro; Pascal Joly; Gérard Socié; Martine Bagot
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

9.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.

Authors:  Rainer Storb; Boglarka Gyurkocza; Barry E Storer; Mohamed L Sorror; Karl Blume; Dietger Niederwieser; Thomas R Chauncey; Michael A Pulsipher; Finn B Petersen; Firoozeh Sahebi; Edward D Agura; Parameswaran Hari; Benedetto Bruno; Peter A McSweeney; Michael B Maris; Richard T Maziarz; Amelia A Langston; Wolfgang Bethge; Lars Vindeløv; Georg-Nikolaus Franke; Ginna G Laport; Andrew M Yeager; Kai Hübel; H Joachim Deeg; George E Georges; Mary E D Flowers; Paul J Martin; Marco Mielcarek; Ann E Woolfrey; David G Maloney; Brenda M Sandmaier
Journal:  J Clin Oncol       Date:  2013-03-11       Impact factor: 44.544

Review 10.  Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation.

Authors:  K E Herbert; A Spencer; A Grigg; G Ryan; C McCormack; H M Prince
Journal:  Bone Marrow Transplant       Date:  2004-09       Impact factor: 5.483
View more
  7 in total

1.  JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL.

Authors:  Sara Yumeen; Fatima N Mirza; Julia M Lewis; Amber Loren O King; Sa Rang Kim; Kacie R Carlson; Sheila R Umlauf; Yulia V Surovtseva; Francine M Foss; Michael Girardi
Journal:  Blood Adv       Date:  2020-05-26

2.  Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis.

Authors:  Florentia Dimitriou; Urs Schanz; Gayathri Nair; Susanne Kimeswenger; Marie-Charlotte Brüggen; Wolfram Hoetzenecker; Lars E French; Reinhard Dummer; Antonio Cozzio; Emmanuella Guenova
Journal:  Front Med (Lausanne)       Date:  2020-06-25

3.  Clinical outcomes and prognostic factors in patients with mycosis fungoides who underwent radiation therapy in a single institution.

Authors:  Bum-Sup Jang; Eunji Kim; Il Han Kim; Hyun-Cheol Kang; Sung-Joon Ye
Journal:  Radiat Oncol J       Date:  2018-06-29

Review 4.  Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome.

Authors:  Xochiquetzal U Martinez; Cosimo Di Raimondo; Farah R Abdulla; Jasmine Zain; Steven T Rosen; Christiane Querfeld
Journal:  Best Pract Res Clin Haematol       Date:  2019-06-06       Impact factor: 3.670

5.  BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition.

Authors:  Sa Rang Kim; Julia M Lewis; Benoit M Cyrenne; Patrick F Monico; Fatima N Mirza; Kacie R Carlson; Francine M Foss; Michael Girardi
Journal:  Oncotarget       Date:  2018-06-26

6.  Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome.

Authors:  Hiroki Hosoi; Kazuo Hatanaka; Shogo Murata; Toshiki Mushino; Kodai Kuriyama; Akinori Nishikawa; Nobuyoshi Hanaoka; Shinobu Tamura; Hideki Nakakuma; Takashi Sonoki
Journal:  Hematol Rep       Date:  2018-09-05

7.  Mycosis Fungoides: Analysis of Ophthalmologic Findings in a Series of Cases.

Authors:  Carina G Colossi; Juliano Mondadori; Pedro K M Barreto; Felipe M Valença; Rodrigo Duquia; Manuel A P Vilela
Journal:  Case Rep Dermatol Med       Date:  2019-01-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.